Switch View
© Newsfile
18.09.2025
ISIN: US71880W5013
Phio Pharmaceuticals Corp.
PHIO
LISTED
NASDAQ
Phio Pharmaceuticals to Present at the Life Sciences Future Conference
News Preview
Key updates to include advances made in the on-going clinical trial for INTASYL siRNA lead product candidate PH-762King of Prussia, Pennsylvania--(Newsfile Corp. - September 18, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biopharmaceutical company developing therapeutics using its proprietary INTASYL® siRNA gene silen...
Themefolio
Profiler
Peergroup
© PR Newswire
18.09.2025
ISIN: US89532M1018
Trevi Therapeutics Inc
TRVI
LISTED
NASDAQ
Trevi Therapeutics Announces Two Posters from the Phase 2a RIVER Trial Data Will be Featured at the European Respiratory Society (ERS) Congress 2025
News Preview
NEW HAVEN, Conn., Sept. 18, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refr...
Themefolio
Profiler
Peergroup
© PR Newswire
18.09.2025
ISIN: US78349D1072
Rxsight Inc
RXST
LISTED
NASDAQ
EXTENDED CLASS PERIOD: Investor Files Class Action Lawsuit Against RxSight, Inc. and Attorneys Announce Opportunity for Investors with Substantial Losses to Lead Class Action Lawsuit
News Preview
SAN DIEGO, Sept. 18, 2025 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that it has filed a class action lawsuit seeking to represent purchasers of RxSight, Inc. (NASDAQ: RXST) common stock between May 7, 2024 and July 8, 2025, inclusive (the "Class Period"). Captioned Gémesi v. RxSight, Inc., No. 25-cv-02093 (C.D...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© Globe Newswire
18.09.2025
ISIN: US76029N1063
Replimune Group Inc
REPL
LISTED
NASDAQ
Replimune Provides Update Following Type A Meeting with FDA
News Preview
WOBURN, Mass., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that the company completed a Type A meeting with the U.S. Food and Drug Administration (FDA) on September 16th to discuss the complete respons...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
18.09.2025
ISIN: US81726A1007
Senti Biosciences, Inc.
SNTI
LISTED
NASDAQ
Senti Bio to Present at the MedInvest Biotech & Pharma Conference
News Preview
Live webcast presentation on Wednesday, September 24th at 9:55 AM PT Live webcast presentation on Wednesday, September 24th at 9:55 AM PT...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.09.2025
ISIN: US8087571084
Scientific Industries, Inc.
SCND
LISTED
OTC
Scientific Industries to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025
News Preview
Investor Presentation to be held at 1:15 p.m. Eastern Time Investor Presentation to be held at 1:15 p.m. Eastern Time...
Themefolio
Profiler
Peergroup
© BusinessWire
18.09.2025
ISIN: US2825591033
89Bio, Inc.
ETNB
LISTED
NASDAQ
ETNB Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of 89bio, Inc. Is Fair to Shareholders
News Preview
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of 89bio, Inc. (NASDAQ: ETNB) to Roche is fair to 89bio shareholders. Under the terms of the proposed transaction, 89bio shareholders will receive $14.50 per share in cash at closing, plus a non-tradeable contingent value right to receive certain contingent payments o...
Themefolio
Profiler
Peergroup
© PR Newswire
18.09.2025
ISIN: CA05156X8504
Aurora Cannabis Inc
ACB
LISTED
NASDAQ
Aurora Announces Investment into German Manufacturing Facility
News Preview
NASDAQ | TSX: ACB
Facility investment includes adopting the company's unmatched global manufacturing practices for superior cannabis production and quality
EDMONTON, AB, Sept. 18, 2025 /CNW/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, announces an investment over five years into op...
Themefolio
Profiler
Peergroup
© PR Newswire
18.09.2025
ISIN: CA05156X8504
Aurora Cannabis Inc
ACB
LISTED
NASDAQ
Aurora Announces Investment into German Manufacturing Facility
News Preview
NASDAQ | TSX: ACB
Facility investment includes adopting the company's unmatched global manufacturing practices for superior cannabis production and quality
EDMONTON, AB, Sept. 18, 2025 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, announces an investment over five years...
Themefolio
Profiler
Peergroup
© BusinessWire
18.09.2025
ISIN: US45784P1012
Insulet Corp
PODD
LISTED
NASDAQ
Insulet and Pantone® Partner to Launch Omnipod® Mango in Vibrant New Palette
News Preview
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, and Pantone®, the global authority on color and provider of professional color standards for the design industries, today announced the creation of Omnipod Mango, a bright and joyful tropical orang...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.09.2025
ISIN: US00439U1043
Grace Therapeutics, Inc.
GRCE
LISTED
NASDAQ
Grace Therapeutics Granted Sixth U.S. Patent Covering I.V. Dosing Regimen for GTx-104
News Preview
Grant of First Method of Use Patent Adds New Pillar to Grace’s Multi-layered Intellectual Property and Potential Market Exclusivity Protection...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.09.2025
ISIN: SG9999014716
WAVE Life Sciences Ltd
WVE
LISTED
NASDAQ
Wave Life Sciences Announces Virtual Research Day on October 29th and Participation at Upcoming Investor Conferences
News Preview
CAMBRIDGE, Mass., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that it will host a virtual Research Day on Wednesday, October 29, 2025 at 10:00 a.m. ET. In addition, members of Wa...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
18.09.2025
ISIN: US0044685008
Achieve Life Sciences, Inc.
ACHV
LISTED
NASDAQ
Achieve Life Sciences Promotes Craig Donnelly to Chief Operations Officer
News Preview
Donnelly brings more than 25 years of biopharmaceutical expertise in CMC and regulatory operations Donnelly brings more than 25 years of biopharmaceutical expertise in CMC and regulatory operations...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.09.2025
ISIN: US18914F1030
Clover Health Investments Corp
CLOV
LISTED
NASDAQ
Clover Health Celebrates the Election of Dr. Ian Duncan, Clover MA Board Member, as the 2025-2026 President-Elect and Vice-Chair of the Society of Actuaries
News Preview
Dr. Duncan's appointment to this prestigious role recognizes his extraordinary contributions to the actuarial profession and healthcare innovation over three decades Dr. Duncan's appointment to this prestigious role recognizes his extraordinary contributions to the actuarial profession and healthcare innovation over three decades...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.09.2025
ISIN: US6283411097
Oncotelic Therapeutics, Inc.
OTLC
LISTED
OTC
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Creating Pioneering Pipeline Designed to Transform Cancer, Rare Diseases Treatments
News Preview
NEW YORK, Sept. 18, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 70+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and cont...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.09.2025
ISIN: CA74764Y2050
Quantum Biopharma Ltd
QNTM
LISTED
NASDAQ
Health Canada Grants Quantum BioPharma a Product License for Its Innovative Product, Qlarity™, that Enhances Energy, and Promotes Metabolism, Mental Alertness and Cognitive Performance
News Preview
TORONTO, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and a...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.09.2025
ISIN: US53216B1044
LifeMD, Inc.
LFMD
LISTED
NASDAQ
LifeMD Expands Pharmacy Services with Non-Sterile Compounding to Deliver Personalized, Cost-Efficient Therapies at Scale
News Preview
Enhanced Affiliated Pharmacy Capabilities Support Specialized Therapies, Seamless Patient Experience, and Margin Expansion Enhanced Affiliated Pharmacy Capabilities Support Specialized Therapies, Seamless Patient Experience, and Margin Expansion...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.09.2025
ISIN: US28657F1030
Elicio Therapeutics, Inc.
ELTX
LISTED
NASDAQ
Elicio Therapeutics Reports Inducement Grants
News Preview
BOSTON, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that on September 15, 2025, Elicio granted an aggregate of 9,800 inducement stock options to two new empl...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.09.2025
ISIN: US8902604094
Tonix Pharmaceuticals Holding Corp.
TNXP
LISTED
NASDAQ
Tonix Pharmaceuticals Announces Positive Pre-IND Meeting with FDA for TNX-102 SL for the Treatment of Major Depressive Disorder
News Preview
Tonix anticipates filing the IND application in the fourth quarter of 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.09.2025
ISIN: IL0011681371
Nano-X Imaging Ltd
NNOX
LISTED
NASDAQ
Nanox Announces Multi-Segment Healthcare Collaboration with Monarch Medical Management to Expand Access to Advanced Medical Imaging
News Preview
Collaboration spans workers' compensation, nursing homes, and outpatient clinics...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.09.2025
ISIN: US36269B1052
Gain Therapeutics, Inc.
GANX
LISTED
NASDAQ
Gain Therapeutics Begins Its GT-02287 Phase 1b Extension Study in People with Parkinson’s Disease
News Preview
Extension of the Phase 1b study will allow participants to continue dosing with GT-02287 for an additional nine months after completing the first 90-day dosing schedule...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.09.2025
ISIN: US09062X1037
Biogen Inc
BIIB
LISTED
NASDAQ
Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates
News Preview
CAMBRIDGE, Mass., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced the company has entered into a definitive agreement to acquire Massachusetts-based Alcyone Therapeutics. As part of an existing partnership with Alcyone Therapeutics, the companies are advancing ThecaFlex DRx™, an implantable subcutaneous port and catheter d...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.09.2025
ISIN: US6036931029
MiNK Therapeutics, Inc.
INKT
LISTED
NASDAQ
MiNK Therapeutics Appoints Dr. Terese C. Hammond to Accelerate iNKT Pipeline to Pivotal Development
News Preview
NEW YORK, Sept. 18, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (Nasdaq: INKT), a clinical-stage biopharmaceutical company pioneering invariant natural killer T (iNKT) cell therapies, today announced the appointment of Terese C. Hammond, MD as Head of Inflammatory and Pulmonary Diseases, effective immediately....
Themefolio
Profiler
Peergroup
© Globe Newswire
18.09.2025
ISIN: US23282W6057
Cytokinetics Inc
CYTK
LISTED
NASDAQ
Cytokinetics Announces Three Upcoming Presentations at the HFSA Annual Scientific Meeting 2025
News Preview
Long-Term Data from FOREST-HCM in Non-Obstructive HCM and Results from Prespecified Analysis of MAPLE-HCM to be Presented in Late-Breaking Clinical Research Session...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.09.2025
ISIN: US4884452065
Zevra Therapeutics Inc
ZVRA
LISTED
NASDAQ
Zevra Therapeutics Announces Upcoming Oral Presentation at the International Niemann-Pick Disease Alliance (INPDA) Meeting and Poster Presentations at the Child Neurology Society (CNS) Conference on MIPLYFFA® (arimoclomol) and OLPRUVA® (sodium phenylbutyr
News Preview
MIPLYFFA, the only therapy for Niemann-Pick disease type C (NPC) shown to stop disease progression at 12 months, has been administered to more than 270 patients, representing the largest data set of NPC clinical trial patients...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.09.2025
ISIN: US45826J1051
Intellia Therapeutics Inc
NTLA
LISTED
NASDAQ
Intellia Therapeutics Completes Enrollment in the Global Phase 3 HAELO Study of Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema
News Preview
CAMBRIDGE, Mass., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced it has completed enrollment in the global Phase 3 HAELO study of lonvoguran ziclumeran (lonvo-z) for the treatment of heredit...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.09.2025
ISIN: US05356F1057
Aveanna Healthcare Holdings Inc
AVAH
LISTED
NASDAQ
Aveanna Healthcare Announces Successful Debt Refinancing
News Preview
ATLANTA, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (“Aveanna”) (Nasdaq: AVAH) today announced the closing of its refinanced first lien credit facility. The refinanced credit facility provides for the refinancing of the $886.0 million principal balance of existing first lien term loans, the additional borrowing of $439.0...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.09.2025
ISIN: US09075P1057
BioXcel Therapeutics, Inc.
BTAI
LISTED
NASDAQ
BioXcel Therapeutics Regains Compliance with Nasdaq Market Value of Listed Securities Requirements
News Preview
NEW HAVEN, Conn., Sept. 18, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that it has received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”)...
Themefolio
Profiler
Peergroup
© PR Newswire
18.09.2025
ISIN: US53216B1044
LifeMD, Inc.
LFMD
LISTED
NASDAQ
LFMD Investors Have Opportunity to Lead LifeMD, Inc. Securities Fraud Lawsuit with the Schall Law Firm
News Preview
LOS ANGELES, Sept. 18, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against LifeMD, Inc. ("LifeMD" or "the Company") (NASDAQ: LFMD) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Sec...
Themefolio
Profiler
Peergroup
© PR Newswire
18.09.2025
ISIN: US81684M1045
Semler Scientific Inc
SMLR
LISTED
NASDAQ
SMLR Investors Have Opportunity to Lead Semler Scientific, Inc. Securities Fraud Lawsuit with the Schall Law Firm
News Preview
LOS ANGELES, Sept. 18, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Semler Scientific, Inc. ("Semler" or "the Company") (NASDAQ: SMLR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by t...
Themefolio
Profiler
Peergroup
© PR Newswire
18.09.2025
ISIN: US8051111016
Savara Inc
SVRA
LISTED
NASDAQ
SVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit with the Schall Law Firm
News Preview
LOS ANGELES, Sept. 18, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Savara Inc. ("Savara" or "the Company") (NASDAQ: SVRA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Secu...
Themefolio
Profiler
Peergroup
© PR Newswire
18.09.2025
ISIN: US5165441032
Lantheus Holdings Inc
LNTH
LISTED
NASDAQ
Lantheus Holdings, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - LNTH
News Preview
LOS ANGELES, Sept. 18, 2025 /PRNewswire/ -- The DJS Law Group announces that it is investigating claims on behalf of investors of Lantheus Holdings, Inc. ("Lantheus" or "the Company") (NASDAQ: LNTH) for violations of the securities laws.
INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and/or...
Themefolio
Profiler
Peergroup
© EQS Newswire
18.09.2025
ISIN: DE000A3MQR65
Viromed Medical AG
Q11
LISTED
XETRA
Erfolgreiche ISO-13485-Zertifizierung ebnet Weg für Markteinführung von ViroCAP® im Oktober 2025
News Preview
Viromed Medical AG: Erfolgreiche ISO-13485-Zertifizierung ebnet Weg für Markteinführung von ViroCAP® im Oktober 2025
Rellingen, 18. September 2025 – Die Viromed Medical AG („Viromed“; ISIN: DE000A3MQR65), ein Medizintechnikunternehmen und Pionier der Kaltplasmatechnologie, hat die ISO-13485-Zertifizierung erhalten. Damit ist Viromed offiziell ein......
Themefolio
Profiler
Peergroup
© EQS Newswire
18.09.2025
ISIN: DE000A3MQR65
Viromed Medical AG
Q11
LISTED
XETRA
Successful ISO 13485 certification paves the way for market launch of ViroCAP® in October 2025
News Preview
Viromed Medical AG: Successful ISO 13485 certification paves the way for market launch of ViroCAP® in October 2025
Rellingen, September 18, 2025 – Viromed Medical AG ("Viromed"; ISIN: DE000A3MQR65), a medical technology company and pioneer of cold plasma technology, has received the ISO 13485 certification. This officially makes Viromed a medical ......
Themefolio
Profiler
Peergroup
© PR Newswire
18.09.2025
ISIN: US02157Q1094
Alto Neuroscience, Inc.
ANRO
LISTED
NYSE
ANRO Investors Have Opportunity to Lead Alto Neuroscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm
News Preview
LOS ANGELES, Sept. 18, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the firm has filed a class action lawsuit against Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE: ANRO) for violations of the federal securities laws....
Themefolio
Profiler
Peergroup
© PR Newswire
18.09.2025
ISIN: US02157Q1094
Alto Neuroscience, Inc.
ANRO
LISTED
NYSE
Alto Neuroscience, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ANRO
News Preview
LOS ANGELES, Sept. 18, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Alto Neuroscience, Inc. ("Alto " or "the Company") (NYSE: ANRO ) for violations of the federal securities laws.
Shareholders who purchased shares of Alto during the class period listed are encouraged to contact the firm regarding po...
Themefolio
Profiler
Peergroup
© BusinessWire
18.09.2025
ISIN: US2825591033
89Bio, Inc.
ETNB
LISTED
NASDAQ
Shareholder Alert: The Ademi Firm Investigates Whether 89bio, Inc. is Obtaining a Fair Price for its Public Shareholders
News Preview
The Ademi Firm is investigating 89bio (Nasdaq: ETNB) for possible breaches of fiduciary duty and other violations of law in its transaction with Roche.
Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you.
Share...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.09.2025
ISIN: DK0062498333
Novo Nordisk A/S
NOVO B
LISTED
CPH
Novo Nordisk A/S: Ozempic® reduces the risk of heart attack, stroke and death by 23% compared to dulaglutide in the first head-to-head real-world study
News Preview
Bagsværd, Denmark, 18 September 2025 – Novo Nordisk today announced results from the REACH real-world study, which demonstrated that compared to dulaglutide, Ozempic® (once-weekly injectable semaglutide) was associated with a reduced risk of major adverse cardiovascular events such as a heart attack or stroke by 23%1. The data span nearly 60,000 US...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
18.09.2025
ISIN: US5845073056
Medical Care Technologies Inc.
MDCE
LISTED
OTC
Medical Care Technologies Inc. Unveils Breakthrough AI for Early Melanoma Detection
News Preview
MESA, ARIZONA / ACCESS Newswire / September 18, 2025 / Medical Care Technologies Inc. (OTC PINK:MDCE), a leader in AI-powered preventive healthcare, today announced a major advancement in dermatology: an artificial intelligence platform designed to revolutionize the early detection of melanoma, the deadliest form of skin cancer.Melanoma accounts fo...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
18.09.2025
ISIN: US87975F1049
Telomir Pharmaceuticals, Inc.
TELO
LISTED
NASDAQ
Telomir Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Targets Additional Histone Demethylase Families, a Unique Profile in Cancer and Aging Not Seen in Other Therapies
News Preview
New in vitro results show Telomir-1 adds KDM5 family inhibition to its previously reported KDM2/KDM6 and DNA methylation activity, potentially representing a novel frontier in epigenetic therapy where no existing candidates have shown comparable breadth. MIAMI, FLORIDA / ACCESS Newswire / September 18, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:T...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
18.09.2025
ISIN: CA58471K2020
Medicus Pharma Ltd.
MDCX
LISTED
TSX
Medicus Pharma Ltd. Announces $8.0 Million Non-Dilutive Debenture Financing
News Preview
The Company plans to use the proceeds to accelerate the development of Teverelix, a next generation GnRH Antagonist, as a first in class market product for Acute Urinary Retention (AURr) and high CV risk Prostate Cancer collecting representing ~ $6 billion in potential market opportunity PHILADELPHIA, PA / ACCESS Newswire / September 18, 2025 / Med...
Themefolio
Profiler
Peergroup
© PR Newswire
18.09.2025
ISIN: US23282W6057
Cytokinetics Inc
CYTK
LISTED
NASDAQ
Do you own shares of CYTK? Robbins LLP Informs Investors of the Cytokinetics, Inc. Class Action Lawsuit
News Preview
SAN DIEGO, Sept. 18, 2025 /PRNewswire/ -- Robbins LLP informs stockholders that a class action was filed on behalf of persons and entities that purchased or otherwise acquired Cytokinetics, Inc. (NASDAQ: CYTK) securities between December 27, 2023 and May 6, 2025. Cytokinetics is a biopharmaceutical company focused on discovering, developing, and...
Themefolio
Profiler
Peergroup
© EQS Newswire
18.09.2025
ISIN: CH1330780979
Curatis Holding AG
CURN
LISTED
SIX
FDA minutes confirm positive outcome of meeting on 9. September 2025 – Corticorelin on track for Phase 3
News Preview
Curatis Holding AG
/ Key word(s): Miscellaneous
FDA minutes confirm positive outcome of meeting on 9. September 2025 – Corticorelin on track for Phase 3
18.09.2025 / 07:00 CET/CEST
MEDIA RELEASE
Liestal, Switzerland, 18. September 2025: Curatis Holding AG (SIX:CURN) received the official minutes from the FDA meeting whi......
Themefolio
Profiler
Peergroup
© EQS Newswire
18.09.2025
ISIN: CH0478634105
Aevis Victoria SA
AEVS
LISTED
SIX
AEVIS VICTORIA SA – Starker Umsatzanstieg im ersten Halbjahr 2025. Der freie Cashflow übersteigt CHF 100 Millionen und ermöglicht einen Schuldenabbau von über CHF 120 Millionen.
News Preview
Ad hoc-Mitteilung gemäss Art. 53 KR
Freiburg, 18. September 2025
AEVIS VICTORIA SA (AEVS.SW) – Starker Umsatzanstieg im ersten Halbjahr 2025.Der freie Cashflow übersteigt CHF 100 Millionen und ermöglicht einen Schuldenabbau von über CHF 120 Millionen.
Die zwei operativen Sparten der Beteiligungsgesellschaft AEVIS VICTORIA SA (AEVIS) haben ihre M......
Themefolio
Profiler
Peergroup
© EQS Newswire
18.09.2025
ISIN: CH0478634105
Aevis Victoria SA
AEVS
LISTED
SIX
AEVIS VICTORIA SA – Strong growth in revenue in the first half of 2025. Free cash flow exceeds CHF 100 million, enabling debt reduction of more than CHF 120 million.
News Preview
Ad hoc announcement pursuant to Art. 53 LR
Fribourg, 18 September 2025
AEVIS VICTORIA SA (AEVS.SW) – Strong growth in revenue in the first half of 2025.
Free cash flow exceeds CHF 100 million, enabling debt reduction of more than CHF 120 million.
The two operating divisions of the investment company AEVIS VICTORIA SA (AEVIS) strengthened the......
Themefolio
Profiler
Peergroup
© ACCESSWIRE
18.09.2025
ISIN: US04537Y1091
Aspira Women's Health Inc.
AWH
LISTED
NASDAQ
Aspira Women's Health Announces Equity Capital Infusion of $3.06 Million in Private Placement and Warrant Exercise
News Preview
$2.95 Million PIPE$112 thousand warrant exercise AUSTIN, TX / ACCESS Newswire / September 18, 2025 / Aspira Women's Health Inc. ("Aspira") (OTCQB:AWHL), an AI enhanced bio-analytics based women's health company focused on delivering leading noninvasive gynecologic disease diagnostics and disease management tools, today announced that it h...
Themefolio
Profiler
Peergroup
© BusinessWire
18.09.2025
ISIN: CH1335392721
Galderma Group AG
GALD
LISTED
XWSX
Galderma Launches Transformative Skincare Segment With Cetaphil’s New Skin Activator Hydrating & Firming Line, in Partnership With Actor and Filmmaker Mariska Hargitay
News Preview
Galderma today announced Cetaphil, the dermatologist-recommended brand trusted by millions with sensitive skin, is redefining daily skincare with its new Skin Activator Hydrating & Firming line. The launch marks an entirely new skincare segment of advanced hydration and firming solutions designed specifically for improving the appearance of ag...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
18.09.2025
ISIN: CA98980M1095
Zomedica Corporation
ZOM
LISTED
XASE
Zomedica Expands TRUVIEW(R) and TRUFORMA(R) Intellectual Property Portfolio with Four Newly Issued U.S. Patents
News Preview
Intellectual property portfolio now includes 228 Patents and 153 Trademarks providing robust protection for the Company's product platforms in the rapidly growing multi-billion dollar veterinary diagnostics market ANN ARBOR, MI / ACCESS Newswire / September 18, 2025 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), a...
Themefolio
Profiler
Peergroup
© PR Newswire
18.09.2025
ISIN: KYG4818G1010
Innovent Biologics Inc
1801
LISTED
HKSE
Innovent's Partner Ollin Announces Clinical Updates on IBI324 (OLN324, VEGF/ANG-2)
News Preview
SAN FRANCISCO and SUZHOU, China, Sept. 18, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major disease areas, to...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.09.2025
ISIN: US2825591033
89Bio, Inc.
ETNB
LISTED
NASDAQ
89bio, Inc. Announces Agreement to be Acquired by Roche
News Preview
– 89bio stockholders to receive up to $20.50 per share in cash, comprised of $14.50 per share in cash at closing and a non-tradeable contingent value right (CVR) to receive up to an aggregate of $6.00 per share in cash; transaction represents total equity value of up to approximately $3.5 billion –...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
18.09.2025
ISIN: CA69016D1087
Ovation Science Inc.
OVAT
LISTED
CSE
Ovation Science and Skinvisible Pharmaceuticals Enhance Their Strategic Partnership in the Obesity Market with Innovative Cannabinoid Delivery Technology with New Developments and Patent Protection
News Preview
VANCOUVER, BC AND LAS VEGAS, NV / ACCESS Newswire / September 18, 2025 / Ovation Science Inc. (CSE:OVAT)(OTC:OVATF) ("Ovation" or the "Company"), today announced an enhanced strategic partnership with Skinvisible Pharmaceuticals, Inc. (OTCQB:SKVI) ("Skinvisible") to leverage patent-pending Invisicare® topical and...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.09.2025
ISIN: FR0014008VX5
Euroapi S.A.
EAPI
LISTED
EURONEXT
Science Based Targets initiative (SBTi) validates EUROAPI’s near-term climate targets
News Preview
September 18, 2025 - EUROAPI’s near-term science-based emission reduction targets have been approved by the Science Based Targets initiative (SBTi1), confirming the company’s alignment with the Paris Agreement trajectory of limiting global warming to 1.5°C above pre-industrial levels....
Themefolio
Profiler
Peergroup
© Globe Newswire
18.09.2025
ISIN: CH0012032048
Roche Holding AG
ROG
LISTED
SIX
Roche enters into a definitive merger agreement to acquire 89bio, and its phase 3 FGF21 analog for the therapy of moderate to severe MASH
News Preview
Basel, 18 September 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has entered into a definitive merger agreement to acquire 89bio, Inc. (Nasdaq: ETNB), a publicly listed clinical-stage biopharmaceutical company pioneering the development of innovative therapies for the treatment of liver and cardiometabolic diseases. 89bio’s peg...
Themefolio
Profiler
Peergroup
© PR Newswire
18.09.2025
ISIN: CNE1000048G6
Remegen Co., Ltd.
9995
LISTED
HKSE
Results of China Phase III Clinical Study of Telitacicept for Generalized Myasthenia Gravis Selected for Oral Presentation at 2025 AANEM Annual Meeting
News Preview
YANTAI, China, Sept. 17, 2025 /PRNewswire/ -- RemeGen (688331.SH/09995.HK) announced that the 48-week open-label extension (OLE) data from China Phase III clinical study of telitacicept (RC18, brand name: 泰爱®, a BLyS/APRIL dual-target fusion protein innovative drug independently developed by RemeGen) for the treatment of generalized myasthenia gr...
Themefolio
Profiler
Peergroup
© PR Newswire
18.09.2025
ISIN: CNE1000048G6
Remegen Co., Ltd.
9995
LISTED
HKSE
Results of China Phase III Clinical Study of Telitacicept for Generalized Myasthenia Gravis Selected for Oral Presentation at 2025 AANEM Annual Meeting
News Preview
YANTAI, China, Sept. 18, 2025 /PRNewswire/ -- RemeGen (688331.SH/09995.HK) announced that the 48-week open-label extension (OLE) data from China Phase III clinical study of telitacicept (RC18, brand name: 泰爱®, a BLyS/APRIL dual-target fusion protein innovative drug independently developed by RemeGen) for the treatment of generalized myasthenia gr...
Themefolio
Profiler
Peergroup
© PR Newswire
18.09.2025
ISIN: KYG1996C1006
CARsgen Therapeutics Holdings Limited
2171
LISTED
HKSE
CARsgen Presents Updated Long-term Follow-up Results for Zevor-cel at IMS 2025
News Preview
SHANGHAI, Sept. 17, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the updated long-term follow-up results of Phase I clinical trial of zevorcabtagene autoleucel (zevor-cel, R&D code: CT053, an autologous CAR T-cell product targe...
Themefolio
Profiler
Peergroup
© PR Newswire
18.09.2025
ISIN: KYG0520K1094
Ascletis Pharma Inc.
1672
LISTED
HKSE
Ascletis Presented Phase III Study Results of First-in-Class FASN Inhibitor Denifanstat (ASC40) for Acne Treatment in the Late Breaking News Sessions of the European Academy of Dermatology and Venereology (EADV) Congress 2025
News Preview
--Denifanstat (ASC40) met all primary, key secondary and secondary efficacy endpoints (ITT analysis) and significantly improved moderate-to-severe acne compared with placebo.
--Denifanstat (ASC40) demonstrated a favorable safety and tolerability profile. Treatment emergent adverse events (TEAEs) in the denifanstat (ASC40) group were comparable to...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.09.2025
ISIN: FR0000121667
EssilorLuxottica SA
EL
LISTED
EURONEXT
EssilorLuxottica: EssilorLuxottica and Meta build on their successful partnership with new AI glasses that offer a glimpse into the future
News Preview
EssilorLuxottica and Meta build on their successful partnershipwith new AI glasses that offer a glimpse into the future...
Themefolio
Profiler
Peergroup
© PR Newswire
18.09.2025
ISIN: US02157Q1094
Alto Neuroscience, Inc.
ANRO
LISTED
NYSE
ANRO Deadline: ANRO Investors Have Opportunity to Lead Alto Neuroscience, Inc. Securities Fraud Lawsuit
News Preview
NEW YORK, Sept. 17, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Alto Neuroscience, Inc. (NYSE: ANRO): (i) pursuant and/or traceable to Alto's initial public offering conducted on or about February 2, 2024 (the "IPO"); and/or (ii) securities between February 2, 2024 and October 22,...
Themefolio
Profiler
Peergroup
© PR Newswire
18.09.2025
ISIN: US5324571083
Eli Lilly and Co
LLY
LISTED
NYSE
Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, reduced A1C by an average of 2.2% in a Phase 3 trial of children and adolescents with type 2 diabetes
News Preview
In SURPASS-PEDS, Mounjaro met the primary and all key secondary endpoints at 30 weeks and showed sustained improvement in glycemic control and continued BMI reduction through the study's 52-week extension
The safety and tolerability profile of Mounjaro was generally consistent with previous adult studies
INDIANAPOLIS, Sept. 17, 2025 /PRNewswire/...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
